BCRB 2018

EORTC Hyperfractionation trial in oropharynx cancer (N = 356)

Oropharyngeal Ca T2-3, N0-1

80.5 Gy - 70 fx - 7 wks vs 70 Gy - 35-40 fx - 7-8 wks

p = 0.02

p = 0.08

SURVIVAL

LOCAL CONTROL

Years

Years

ESTRO

Horiot 1992